Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

DH, Yoo; N, Prodanovic; J, Jaworski; P, Miranda; E, Ramiterre; A, Lanzon; A, Baranauskaite; P, Wiland; C, Abud-Mendoza; B, Oparanov; S, Smiyan; H, Kim; SJ, Lee; S, Kim; W, Park

doi:10.1136/annrheumdis-2015-208786

Public

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

Shared by NobleBlocks on Apr 29, 2016 • 12:00 AM UTC

Authors:

Yoo DH

Prodanovic N

Jaworski J

Abstract

Objectives To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions.Methods This open-label extension study recruit...

Subject

Rheumatoid arthritis

Treatment

Anti-tnf

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!